Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Qiagen ( (QGEN) ) just unveiled an announcement.
On April 27, 2026, Qiagen reported preliminary first-quarter 2026 results showing net sales of $492 million, up 2% on a reported basis but down 1% at constant exchange rates, while adjusted EPS of $0.54 met guidance and profitability remained robust. Growth pillars such as sample technologies, QIAcuity and Qiagen Digital Insights delivered solid gains, but QuantiFERON sales fell 5% at constant exchange rates due mainly to a sharp drop in U.S. and Middle East immigration testing demand, highlighting ongoing weakness among U.S. life-sciences customers.
The company cut its full-year 2026 constant-currency sales growth outlook to about 1–2% from at least 5% and trimmed its adjusted EPS target to at least $2.43, citing reduced QuantiFERON immigration volumes, customer caution and geopolitical uncertainty. Management signalled expectations for stronger momentum in the second half of 2026 as headwinds from discontinued product lines fade, recent assay launches ramp and the Parse acquisition outperforms initial plans, a trajectory closely watched by investors assessing Qiagen’s medium-term growth profile.
The most recent analyst rating on (QGEN) stock is a Hold with a $34.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
Spark’s Take on QGEN Stock
According to Spark, TipRanks’ AI Analyst, QGEN is a Neutral.
The score is supported primarily by improved 2025 profitability and solid operating/free cash flow with manageable leverage, plus constructive 2026 guidance. These positives are tempered by very weak technicals (price far below key moving averages and bearish MACD) and some fundamental consistency risks (historical earnings/FCF volatility and near-term headwinds impacting early 2026).
To see Spark’s full report on QGEN stock, click here.
More about Qiagen
Qiagen N.V. is a Netherlands-based life-sciences and diagnostics company that develops sample preparation technologies, molecular testing platforms such as QIAcuity digital PCR and QIAstat-Dx, and bioinformatics solutions under Qiagen Digital Insights. The group focuses on clinical diagnostics, including its QuantiFERON latent TB test, and tools for pharmaceutical and academic research customers worldwide.
Average Trading Volume: 2,077,340
Technical Sentiment Signal: Sell
Current Market Cap: $7.13B
For an in-depth examination of QGEN stock, go to TipRanks’ Overview page.